Australia markets closed

Chimerix, Inc. (CMRX)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
1.0400-0.0050 (-0.48%)
At close: 04:00PM EDT
1.0495 +0.01 (+0.91%)
After hours: 07:45PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.0450
Open1.0500
Bid1.0400 x 3200
Ask1.0500 x 1800
Day's range1.0200 - 1.0500
52-week range0.9200 - 2.4000
Volume218,410
Avg. volume700,954
Market cap92.127M
Beta (5Y monthly)1.11
PE ratio (TTM)0.51
EPS (TTM)2.0200
Earnings date01 Nov 2023 - 06 Nov 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est7.00
  • GlobeNewswire

    Chimerix to Participate in Upcoming Investor Conferences

    DURHAM, N.C., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that management will participate in two upcoming investor conferences: H.C. Wainwright 25th Annual Global Investment Conference in New York City. Mike Andriole, Chief Executive Officer, will present a corporate overview on September 12, 2023 at 9:00 a.m. ET. A l

  • GlobeNewswire

    Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to ONC201 Treatment of H3 K27M-Mutant Diffuse Midline Gliomas Published in "Cancer Discovery"

    Patients Treated with ONC201 Demonstrated Median Overall Survival (mOS) of 21.7 Months in the Front-Line Setting, Post Radiation, Versus 12 Months mOS Historical Control ONC201 Treatment Disrupts Key Metabolic and Epigenetic Pathways DURHAM, N.C., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the publication of data in

  • Zacks

    Chimerix (CMRX) Reports Q2 Loss, Misses Revenue Estimates

    Chimerix (CMRX) delivered earnings and revenue surprises of 8.70% and 95.91%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?